Spectrum Pharmaceuticals Inc SPPI:NASDAQ

Last Price$1.21NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/11/22

Today's Change+0.09(8.04%)
Bid (Size)$1.22 (4)
Ask (Size)$1.30 (89)
Day Low / High$1.20 - 1.29

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/11/2022


Spectrum Pharmaceuticals Inc ( NASDAQ )

Price: $1.21
Change: +0.09 (8.04%)
Volume: 265.00
4:00PM ET 8/11/2022

Harrow Health Inc ( NASDAQ )

Price: $8.54
Change: +0.89 (11.63%)
Volume: 116.4 K
4:00PM ET 8/11/2022

Allakos Inc ( NASDAQ )

Price: $3.60
Change: -0.23 (6.01%)
Volume: 621.6 K
4:00PM ET 8/11/2022

Assertio Holdings Inc ( NASDAQ )

Price: $3.80
Change: -0.20 (5.00%)
Volume: 100.00
4:00PM ET 8/11/2022

Matinas BioPharma Holdings Inc ( NYSE MKT LLC )

Price: $0.85
Change: -0.04 (4.22%)
Volume: 1.3 M
8:00PM ET 8/11/2022

Read more news Recent News

Spectrum Pharmaceuticals Names Nora Brennan CFO
7:58AM ET 5/11/2022 MT Newswires

Spectrum Pharmaceuticals (SPPI) said Wednesday that it has appointed Nora Brennan as chief financial officer, effective May 25. Brennan has served on...

Spectrum Pharmaceuticals Says FDA Accepts Eflapegrastim Biologics License Application Resubmission; Shares Up Pre-Bell
7:24AM ET 4/11/2022 MT Newswires

Spectrum Pharmaceuticals (SPPI) said Monday the US Food and Drug Administration has accepted its resubmission of the Biologics License Application for...

--B. Riley Lowers Spectrum Pharmaceuticals' Price Target to $4 from $6 to Account for Slightly Delayed Market Entry of Pozi, Efla; Keeps Buy Rating
9:20AM ET 3/21/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Spectrum Pharmaceuticals Q4 Loss Narrows
4:13PM ET 3/17/2022 MT Newswires

Spectrum Pharmaceuticals (SPPI) late Thursday reported a Q4 non-GAAP net loss of $0.17 per share, narrowing from a loss of $0.20 per share a year earlier....

Company Profile

Business DescriptionSpectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Henderson, NV. View company web site for more details
Address11500 South Eastern Avenue
Henderson, Nevada 89052
Number of Employees235
Recent SEC Filing08/11/20228-K
President, CEO, CFO & DirectorThomas J. Riga
Chief Medical Officer & Executive Vice PresidentFrancois Lebel
Senior Vice President-Clinical DevelopmentLyndah K. Dreiling
Secretary, Chief Legal Officer & Executive VPKeith M. McGahan

Company Highlights

Price Open$1.25
Previous Close$1.21
52 Week Range$0.60 - 2.53
Market Capitalization$217.9 M
Shares Outstanding180.1 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.86
Beta vs. S&P 500N/A
Revenue$109.3 M
Net Profit MarginN/A
Return on Equity-190.00%

Analyst Ratings as of 03/25/2022

Consensus RecommendationConsensus Icon
Powered by Factset